Aletekitug Biosimilar Monoclonal Antibody (IL-18) for Research

Cat No.: GMP-Bios-INN-1071

Anti-IL18 therapeutic antibody (Pre-made Aletekitug biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Aletekitug (development code GSK-1070806) is a monoclonal antibody targeting interleukin-18 (IL-18). It is developed by GSK for atopic dermatitis. It is in Phase II clinical development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1071-1mg 1mg 3090
GMP-Bios-INN-1071-10mg 10mg
GMP-Bios-INN-1071-100mg 100mg
GMP-Bios-INN-1071-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Aletekitug biosimilar, Whole mAb, Anti-IL18 Antibody: Anti-IL-18/IL18/Interleukin-18/Iboctadekin therapeutic antibody
INN Name Aletekitug
Target IL18
Format Whole mAb
Derivation Humanized
Species Reactivity Human
CH1+2+3 Isotype G1
VD LC Kappa
Highest_Clin_Trial (Jan '20) Phase-II
Est. Status Active
100% SI Structure None
99% SI Structure None
95-98% SI Structure None
Year Proposed 2024
Year Recommended na
Companies GSK
Conditions Approved na
Conditions Active Atopic dermatitis
Conditions Discontinued Crohn's disease;Delayed graft function;Inflammatory bowel diseases;Type 2 diabetes mellitus
Production na
Development Tech na